Novo Holdings Completes Acquisition of 博彩游戏
博彩游戏 to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership
SOMERSET, NJ and COPENHAGEN, Denmark 鈥 December 18, 2024 鈥 博彩游戏. (鈥湶┎视蜗封), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (鈥淣ovo Holdings鈥), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of 博彩游戏 in an all-cash transaction with a total enterprise value of approximately $16.5 billion.
Alessandro Maselli, who will remain President and Chief Executive Officer of 博彩游戏, said, 鈥淭he completion of this transaction marks a significant milestone for 博彩游戏. As a private company with Novo Holdings鈥 partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders. I would like to thank all of our employees for their commitment to making 博彩游戏 the incredible company it is today, and I am excited for all that we will accomplish going forward.鈥
Kasim Kutay, CEO of Novo Holdings, said, 鈥淲e are pleased to welcome Alessandro and the talented 博彩游戏 team to the Novo Holdings family. 博彩游戏 plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings鈥 purpose to invest for the benefit of people and the planet.鈥
鈥淲e look forward to supporting the 博彩游戏 team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally,鈥 added Jonathan Levy, Senior Partner, Novo Holdings.
With the completion of the transaction, holders of 博彩游戏 common stock are entitled to receive $63.50 per share in cash, representing a premium of approximately 47.5% to the 60-day volume-weighted average price as of February 2, 2024. 博彩游戏鈥檚 common stock has ceased trading and will be delisted from the New York Stock Exchange.
Shortly following the completion of the transaction, Novo Nordisk A/S will acquire from Novo Holdings 博彩游戏鈥檚 three fill-finish sites located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium, and related assets.
Advisors
Citi and J.P. Morgan served as financial advisors to 博彩游戏. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to 博彩游戏 and Jones Day served as legal advisor to the 博彩游戏 Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Davis Polk & Wardwell LLP and Arnold & Porter Kaye Scholer LLP served as legal advisors to Novo Nordisk.
ABOUT CATALENT
博彩游戏. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. 博彩游戏 is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, 博彩游戏 supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, 博彩游戏 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people鈥檚 health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.
About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people鈥檚 health and the sustainability of society and the planet. The Foundation鈥檚 mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
Contacts:
博彩游戏
Investor Contact:
Paul Surdez
+1 (732) 537-6325
[email protected]
Media Contact:
Laura Hortas
+1(609) 240-7025
[email protected]
Novo Holdings
(Global inquiries) Marie-Louise Jersin, Senior Communications Partner
(US inquiries) Dora Gonzalez, Public Relations Specialist
[email protected]